SynthesisLupus2023
Cardiovascular events and risk in patients with systemic lupus erythematosus: Systematic literature review and meta-analysis.
Synthesis in Lupus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk of myocardial infarction in patients with multiple sclerosis: a systematic review and meta-analysis.BMC neurology · 2026Pooled it
- Comparison of cardiac MRI features of fibrosis and strain for early cardiac dysfunction assessment in patients with systemic lupus erythematosus and Sjögren's syndrome.Lupus science & medicine · 2026Article
- Metabolic Complications in Autoimmune and Autoinflammatory Diseases: Pathophysiology, Clinical Implications, and Therapeutic Perspectives.Journal of clinical medicine · 2026Review
- Metabolomics and cardiovascular risk factors in autoimmune-mediated connective tissue diseases - an exploratory, hypothesis-generating study.BMC rheumatology · 2026Article
- [Austrian lipid consensus : Interdisciplinary evidence-based recommendations on prevention and treatment of lipid-associated diseases from 15 medical specialist societies].Wiener klinische Wochenschrift · 2026Article
- Use of advanced cardiovascular imaging in rheumatic immune-mediated inflammatory diseases.Rheumatology (Oxford, England) · 2026Article
- Leukocyte Telomere Length and Long-Term Clinical Outcomes in Women with Systemic Lupus Erythematosus: A Prospective Cohort Study.Journal of clinical medicine · 2026Article
- Cluster of Differentiation 36-Mediated Inflammation and Lipid Metabolism in Cardiovascular Diseases: From Mechanisms to Novel Therapies.Antioxidants (Basel, Switzerland) · 2026Review
- Stroke in autoimmune rheumatic diseases.Rheumatology international · 2026Review
- The current state of systemic lupus erythematosus care in the Philippines: a narrative review.Journal of rheumatic diseases · 2026Review
- Multimodal Cardiac Imaging in Systemic Lupus Erythematosus: From Clinical Suspicion to Diagnosis in Clinical Practice.Diagnostics (Basel, Switzerland) · 2026Review
- Serum IL-2 levels are associated with disease activity and related to dyslipidaemia and the immunological profile in systemic lupus erythematosus.Lupus science & medicine · 2026Article
- Reduced C3 Levels Link Dyslipidemia and Renal Involvement in Systemic Lupus Erythematosus.Journal of inflammation research · 2026Article
- The shared biomarkers and molecular mechanisms of systemic lupus erythematosus and type 2 diabetes.PloS one · 2026Article
- Cardiovascular Disorders in Systemic Lupus Erythematosus.Current vascular pharmacology · 2026Review
- Cardiovascular risk stratification in inflammatory-driven conditions: how far have we come?Frontiers in cardiovascular medicine · 2026Review
- Plasma catecholamine metabolites are associated with disease activity and pathophysiological features in systemic lupus erythematosus using targeted LC-MS/MS.Scientific reports · 2025Article
- Myocardial infarction in rheumatic diseases.Rheumatology international · 2025Review
- Finerenone as a Nonsteroidal Mineralocorticoid Receptor Antagonist for Lupus Nephritis.Kidney international reports · 2025Article
- Enhancing predictions of subclinical cardiac dysfunction in SLE patients through integrative machine learning analysis.Lupus science & medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic lupus erythematosus (SLE) is an autoimmune disease that typically affects women aged 16-55 years. Cardiovascular disease (CVD) is a well-recognized complication of SLE. This systematic literature review and meta-analysis evaluated the relative risk (RR; compared with non-SLE controls), absolute risk (AR; as incidence proportion, n/N), and incidence rate (IR) of CVD events (including stroke, myocardial infarction [MI], and CVD [composite or undefined]) in adult patients with SLE. The RR of CV risk factors (including hypertension, diabetes, and metabolic syndrome [MetS]) was also examined.
methodsPubMed and Embase were searched on September 10, 2020. Observational studies published between January 2010 and September 2020 that reported RR, AR, and/or IR of CVD events, or RR of CV risk factors, were eligible. Pooled risk estimates were calculated using a random-effects model.
resultsForty-six studies (16 cross-sectional, 15 retrospective cohort, 14 prospective cohort, and 1 case-control) were included in meta-analyses. Most studies were considered high quality (Critical Appraisal Skills Programme checklists). Compared with adults without SLE, patients with SLE had statistically significantly higher RRs (95% CIs) of stroke (2.51 [2.03-3.10]; 12 studies), MI (2.92 [2.45-3.48]; 11 studies), CVD (2.24 [1.94-2.59]; 8 studies), and hypertension (2.70 [1.48-4.92]; 7 studies). RRs of diabetes (1.24 [0.78-1.96]; 3 studies) and MetS (1.49 [0.95-2.33]; 7 studies) were elevated but not significant. RRs of stroke and MI were generally higher in younger versus older patients with SLE. In patients with SLE, the pooled estimate of AR (95% CI) was 0.03 (0.02-0.05), 0.01 (0.00-0.02), and 0.06 (0.03-0.10) for stroke (7 studies), MI (6 studies), and CVD (8 studies), respectively. The pooled estimate of IR per 1000 person-years (95% CI) was 4.72 (3.35-6.32), 2.81 (1.61-4.32), and 11.21 (8.48-14.32) for stroke (10 studies), MI (6 studies), and CVD (8 studies), respectively. Although heterogeneity (based on I
conclusionsThis meta-analysis found an increased risk of stroke, MI, CVD, and hypertension in patients with SLE compared with the general population, despite substantial heterogeneity across the included studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.